Pharmacy Benefit Management

From Drug Benefit News - Alzheimer’s disease is ranked as one of the leading causes of death, and with a huge older U.S. population, incidence of the disease is only expected to rise. Innovation has not kept pace — but after a decade when Alzheimer’s drug development saw almost a 100% failure rate, there are now multiple drugs in late-stage clinical trials that could hit the market as early as 2018. Now the question is whether the U.S. health care system is prepared to put these innovative new treatments into practice. Read more

From Specialty Pharmacy News - One year after the FDA approved the first biosimilar drug, Zarxio (filgrastim-sndz), the Sandoz, Inc. drug is making some headway within the short-acting granulocyte colony-stimulating factor class of drugs. But there are some lessons that other biosimilar manufacturers may want to take to heart as they attempt to break into the U.S. Read more

Pharmacy Benefit Management Blog

By Lauren Flynn Kelly - April 14, 2016
In the latest squabble between drugstores and PBMs, the National Community Pharmacists Association (NCPA) on April 1 issued a letter to CMS Deputy Director Cynthia Tudor asserting that Medicare Part D plans and PBMs are not complying with a federal requirement to use drug pricing standards that “...
By Angela Maas - March 30, 2016
As high drug prices continue to make headlines and draw congressional ire, hepatitis C drugs and “Mr. Wu-Tang” Martin Shkreli seem to be getting a reprieve as focus turns to the prostate cancer drug Xtandi. On March 28, 12 members of Congress sent a letter to HHS Sec. Sylvia Burwell and Francis...
By Lauren Flynn Kelly - March 4, 2016
Since the introduction of direct-acting antivirals that in clinical trials demonstrated higher sustained virologic response (SVR) rates in hepatitis C patients than ever before, we’ve seen figures on sales, treatment costs, adherence levels, etc. For example, Harvoni (ledipasvir and sofosbuvir) and...

It's quick and easy to sign up for FREE access to!

Why do I need to register?